CN102224168B - 用于生产抗淀粉状蛋白β肽抗体的含有D-肽的组合物 - Google Patents

用于生产抗淀粉状蛋白β肽抗体的含有D-肽的组合物 Download PDF

Info

Publication number
CN102224168B
CN102224168B CN200980146026.4A CN200980146026A CN102224168B CN 102224168 B CN102224168 B CN 102224168B CN 200980146026 A CN200980146026 A CN 200980146026A CN 102224168 B CN102224168 B CN 102224168B
Authority
CN
China
Prior art keywords
amyloid beta
peptide
beta peptide
binds
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980146026.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102224168A (zh
Inventor
D·威尔伯尔德
C·科尔特
A·米勒-施夫曼
S·A·丰克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungszentrum Juelich GmbH
Original Assignee
Forschungszentrum Juelich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungszentrum Juelich GmbH filed Critical Forschungszentrum Juelich GmbH
Publication of CN102224168A publication Critical patent/CN102224168A/zh
Application granted granted Critical
Publication of CN102224168B publication Critical patent/CN102224168B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN200980146026.4A 2008-11-19 2009-11-17 用于生产抗淀粉状蛋白β肽抗体的含有D-肽的组合物 Expired - Fee Related CN102224168B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008037564A DE102008037564A1 (de) 2008-11-19 2008-11-19 Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
DE102008037564.0 2008-11-19
PCT/EP2009/065308 WO2010057882A2 (de) 2008-11-19 2009-11-17 Zusammensetzung zur herstellung von anti-amyloid beta-peptid-antikörpern mit d-peptiden

Publications (2)

Publication Number Publication Date
CN102224168A CN102224168A (zh) 2011-10-19
CN102224168B true CN102224168B (zh) 2015-03-25

Family

ID=41572521

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980146026.4A Expired - Fee Related CN102224168B (zh) 2008-11-19 2009-11-17 用于生产抗淀粉状蛋白β肽抗体的含有D-肽的组合物

Country Status (6)

Country Link
US (1) US9051364B2 (https=)
EP (1) EP2356144B1 (https=)
JP (1) JP6029280B2 (https=)
CN (1) CN102224168B (https=)
DE (1) DE102008037564A1 (https=)
WO (1) WO2010057882A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10428127B2 (en) 2013-09-26 2019-10-01 Forschungszentrum Juelich Gmbh Cyclic, amyloid beta-binding peptides and the use thereof

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010017130B4 (de) * 2010-05-28 2018-11-29 Forschungszentrum Jülich GmbH Hybrid-Verbindung, deren Verwendung und Verfahren zu deren Herstellung
EP2723363B1 (en) 2011-06-24 2018-08-29 NoNO Inc. Combination therapy for ischemia
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
DK2834643T3 (da) * 2012-04-05 2020-02-03 Forschungszentrum Juelich Gmbh Fremgangsmåde til behandling af blod, blodprodukter og organer
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
EP2834644B1 (de) * 2012-04-05 2019-08-21 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente amyloid-beta-bindende d-peptide und deren verwendung
DE102012102998B4 (de) * 2012-04-05 2013-12-05 Forschungszentrum Jülich GmbH Polymere, enthaltend multivalente Amyloid-Beta-bindende D-Peptide und deren Verwendung
DE102014003262A1 (de) 2014-03-12 2015-09-17 Forschungszentrum Jülich GmbH Amyloid-Beta-bindende Peptide und deren Verwendung für die Therapie und die Diagnose der Alzheimerschen Demenz
EP3747454B9 (de) 2013-09-26 2023-10-04 Priavoid GmbH Amyloid-beta-bindende peptide und diese peptide zur verwendung für die therapie und die diagnose der alzheimerschen demenz
DE102015003676A1 (de) * 2015-03-20 2016-09-22 Forschungszentrum Jülich GmbH Fachbereich Patente Spezifisch A-Beta Spezies bindende Peptide für die Therapie und/oder die Diagnose der Alzheimerschen Demenz
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1091138A (zh) * 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
WO2002081505A2 (de) * 2001-04-06 2002-10-17 imb Institut für molekulare Biotechnologie e.V. Peptid zur diagnose und therapie der alzheimer-demenz

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277826B1 (en) * 1996-08-27 2001-08-21 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
ATE366259T1 (de) 1999-03-04 2007-07-15 Praecis Pharm Inc Beta-amyloid-peptidaggregation regulierende peptide mit d-aminosäuren
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US20050026165A1 (en) * 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
JP4696079B2 (ja) * 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1091138A (zh) * 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
WO2002081505A2 (de) * 2001-04-06 2002-10-17 imb Institut für molekulare Biotechnologie e.V. Peptid zur diagnose und therapie der alzheimer-demenz

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A liposome-based therapeutic vaccine against β-amyloid plaques on the pancreas of transgenic NORBA mice;Claude Nicolau,et al;《Proceedings of the National Academy of Sciences of the United States》;20020219;第99卷(第4期);2332-2337 *
Beka Solomon,et al.Disaggregation of Alzheimer β-amyloid by site-directed mAb.《Proceedings of the National Academy of Sciences of the United States》.1997,第94卷 *
Disaggregation of Alzheimer β-amyloid by site-directed mAb;Beka Solomon,et al;《Proceedings of the National Academy of Sciences of the United States》;19970430;第94卷;4109-4112 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10428127B2 (en) 2013-09-26 2019-10-01 Forschungszentrum Juelich Gmbh Cyclic, amyloid beta-binding peptides and the use thereof

Also Published As

Publication number Publication date
DE102008037564A1 (de) 2010-05-20
US20110243949A1 (en) 2011-10-06
EP2356144A2 (de) 2011-08-17
CN102224168A (zh) 2011-10-19
EP2356144B1 (de) 2018-07-04
US9051364B2 (en) 2015-06-09
JP6029280B2 (ja) 2016-11-24
JP2012509295A (ja) 2012-04-19
WO2010057882A2 (de) 2010-05-27
WO2010057882A3 (de) 2010-07-22

Similar Documents

Publication Publication Date Title
CN102224168B (zh) 用于生产抗淀粉状蛋白β肽抗体的含有D-肽的组合物
CN102123728B (zh) 用于治疗淀粉样变的化合物
JP6174727B2 (ja) 治療的特性を有するβ１〜４２特異的モノクローナル抗体
JP2022180615A (ja) 病理学的タウタンパク質の免疫学的標的化方法
CN102123727B (zh) 用于治疗β-淀粉样变的化合物
AU2006326283B2 (en) Therapeutic vaccine
ES2766762T3 (es) Inmunoterapia contra Tau
US8741298B2 (en) APOE immunotherapy
JP5722770B2 (ja) アミロイド折りたたみ中間体に対するワクチン
KR20030066695A (ko) 베타 아밀로이드 펩티드를 인식하는 인간화된 항체
JP2006516116A (ja) Ｓｙｎｕｃｌｅｉｎ病の予防および治療
KR20110036809A (ko) 파킨슨병과 관련된 증상을 치료하기 위한 화합물
JP5474807B2 (ja) 改変アミロイドβペプチド
WO2013012811A2 (en) Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
CN101325972B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体
Li et al. Prophylactic vaccine based on pyroglutamate-3 amyloid β generates strong antibody response and rescues cognitive decline in Alzheimer’s disease model mice
KR100829447B1 (ko) 프리온 단백질의 진전병 동형체들을 선택적으로 검출할 수있는 항체
HK1124532A (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
HK1124532B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150325

Termination date: 20191117

CF01 Termination of patent right due to non-payment of annual fee